• Hexa His Tag Peptide: Mechanistic Insight and Translational

  2026-04-17

  This article advances the conversation on the Hexa His tag peptide by integrating mechanistic understanding with experimental rigor and strategic guidance, offering translational researchers a roadmap for reproducible, high-purity protein purification and interaction studies. Drawing from recent biochemical research and comparative analyses, we highlight how the Hexa His tag peptide (6X His tag peptide) not only addresses persistent workflow challenges such as antibody contamination and elution efficiency, but also positions itself as an essential tool in emerging clinical and functional proteomics pipelines.

• Resazurin Sodium Salt: Fluorogenic Indicator for Cell Viabil

  2026-04-16

  Resazurin sodium salt is revolutionizing cell viability and cytotoxicity assays with its robust redox sensitivity and compatibility with modern high-throughput workflows. This guide provides actionable protocols, troubleshooting insights, and real-world use-cases, highlighting the compound’s pivotal role in dissecting metabolic pathways and therapeutic responses in disease models.

• PSMD13 as a Prognostic and Immunological Marker in LIHC

  2026-04-15

  This study provides a systematic analysis of PSMD13, a 26S proteasome subunit, revealing its upregulation in liver hepatocellular carcinoma (LIHC) and strong association with poor prognosis and the tumor immune microenvironment. By integrating bioinformatics, clinical tissue immunohistochemistry, and functional assays, the research establishes PSMD13 as a candidate biomarker for LIHC prognosis and immune status profiling.

• PLGA-Based Nano-Adjuvant Enhances Mucosal Immunity in Chicks

  2026-04-14

  This study introduces a PLGA-based nano-adjuvant (PEI-LSP-RA-PLGA) that significantly improves both mucosal and systemic immune responses in chicks receiving an inactivated H9N2 influenza vaccine. The results highlight the adjuvant's ability to target the intestine, sustain antigen release, and increase IgA production, offering a promising strategy for poultry vaccine enhancement.

• Mitochondrial Vulnerabilities in Acute Myeloid Leukemia: Ins

  2026-04-13

  Panina et al. (2019) identify acute myeloid leukemia (AML) as uniquely sensitive to mitochondrial-targeting anticancer drugs (mitocans), due to metabolic defects in mitochondrial function. Their integrative approach informs future research on selective cancer therapeutics and highlights rational strategies for combinatorial targeting of mitochondrial and glycolytic pathways.

• HA Tag Peptide in Chemoproteomic Discovery: Beyond Protein P

  2026-04-12

  Explore the multifaceted role of Influenza Hemagglutinin (HA) Peptide in advanced chemoproteomics and molecular oncology. This article reveals how the HA tag peptide enables precise protein purification and interaction studies, and examines its impact on modern cancer research.

• RapaLink-1: Redefining mTORC1 Inhibition for Dormancy and On

  2026-04-12

  Discover how RapaLink-1, a pioneering third-generation mTOR inhibitor, enables precise control of mTORC1 signaling for both embryonic dormancy research and advanced cancer models. This article delivers a unique, protocol-driven perspective grounded in reference innovation.

• Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibi

  2026-04-11

  Anlotinib hydrochloride stands out as a next-generation multi-target tyrosine kinase inhibitor for advanced cancer and angiogenesis research. Its superior selectivity for VEGFR2, PDGFRβ, and FGFR1—paired with robust pharmacokinetics—empowers precise functional assays and translational workflows.

• Rotigotine Hydrochloride: Dopamine D2/D3 Agonist in PD Resea

  2026-04-11

  Rotigotine hydrochloride empowers precise Parkinson’s disease modeling and dopaminergic signaling studies through validated dosing, high receptor selectivity, and robust workflow compatibility. This guide distills protocol enhancements, troubleshooting insights, and impurity management strategies—helping labs achieve reproducible, high-impact results with APExBIO’s A3777.

• Rotigotine Hydrochloride: Multi-Receptor Agonist for Neur...

  2026-04-10

  Discover the scientific basis and translational potential of Rotigotine hydrochloride, a dopamine D2/D3 receptor agonist with broad receptor affinity and robust neuroprotective effects. This article uniquely explores its multi-receptor mechanisms, advanced applications in animal and cellular models, and its future in dopaminergic drug development.

• Rotigotine Hydrochloride: Advanced Mechanistic Insights f...

  2026-04-09

  Explore the multifaceted roles of Rotigotine hydrochloride, a potent dopamine D2/D3 receptor agonist, in both motor and non-motor Parkinson’s disease research. This in-depth article uniquely delves into its mechanistic actions, neuroprotection, and translational applications beyond standard models.

• Rotigotine hydrochloride: Dopamine D2/D3 Agonist for Neur...

  2026-04-08

  Rotigotine hydrochloride is a non-ergot dopamine D2/D3 receptor full agonist used as a benchmark antiparkinsonian agent and for dopaminergic signaling research. Its validated neuroprotective and antioxidant properties are supported by robust in vitro and in vivo evidence, making it essential for Parkinson's disease and restless legs syndrome research.

• Rotigotine Hydrochloride: Translating Mechanistic Dopamin...

  2026-04-08

  Rotigotine hydrochloride, a full-spectrum dopamine receptor agonist with robust affinity for D2/D3 subtypes and additional serotonergic and adrenergic activity, is redefining the landscape for translational neuroscience. This article provides a strategic, mechanistic, and application-focused exploration of Rotigotine hydrochloride’s role in advancing Parkinson’s disease and restless legs syndrome research, moving beyond standard product overviews to deliver actionable guidance for experimental design, model selection, and translational impact.

• Rotigotine hydrochloride: Dopamine D2/D3 Agonist for Neur...

  2026-04-07

  Rotigotine hydrochloride is a full dopamine D2/D3 receptor agonist and benchmark antiparkinsonian agent with robust neuroprotective and antidepressant properties. Its well-defined receptor profile and validated delivery routes make it a gold standard for dopaminergic signaling and neurodegeneration research. This article details actionable parameters, proven applications, and common misconceptions for research use.

• Rotigotine Hydrochloride: Dopamine D2/D3 Receptor Agonist...

  2026-04-07

  Rotigotine hydrochloride is a non-ergot dopamine D2/D3 receptor agonist widely used as an antiparkinsonian agent and in dopaminergic signaling research. This article delivers evidence-based insights on its mechanism, benchmarks, and practical integration for neurodegenerative disease models.

448 records 21/30 page Previous Next First page 上5页 2122232425 下5页 Last page